By Rob Curran

Vaxcyte said Thursday that the Food and Drug Administration cleared its investigational new drug application for a pneumococcal-infection vaccine.

The San Carlos, Calif., vaccine developer plans to initiate a Phase 1/2 clinical trial, testing the VAX-31 drug candidate on adults, in the fourth quarter.

Vaxcyte anticipates reporting topline safety, tolerability and immunogenicity results in the second half of 2024, Chief Executive and co-founder Grant Pickering said.

Earlier this week, Vaxcyte expanded its collaboration with Lonza to establish global commercial manufacturing capacity for VAX-31 and VAX-24 for adults and children.

Write to Rob Curran at rob.curran@wsj.com

(END) Dow Jones Newswires

October 19, 2023 09:14 ET (13:14 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Vaxcyte (NASDAQ:PCVX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Vaxcyte Charts.
Vaxcyte (NASDAQ:PCVX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Vaxcyte Charts.